Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS

Several studies link the gut microbiome and MS immunopathogenesis. Fecal microbiota transplantation (FMT), the process of transferring fecal microbiota from a healthy donor to a patient, successfully treats recurrent Clostridium difficile enterocolitis and may benefit autoimmune diseases. The potential short-term efficacy of this procedure has been reported in MS. Here, we describe a patient with secondary progressive MS (SPMS) who achieved disease stability for over 10 years following FMT.